Polar Capital’s Revance Therapeutics, Inc. RVNC Stock Holding History

Polar Capital’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	$28.1M	Sell	1,115,804 -167,409	-13%	-$4.39M	0.21%	108
2020 Q2	$31.3M	Buy	1,283,213 +1,263,279	+6,337%	+$24.9M	0.27%	98
2020 Q1	$295K	Sell	19,934 -725,201	-97%	-$15M	﹤0.01%	281
2019 Q4	$12.1M	Buy	+745,135	New	+$11.6M	0.11%	186
2017 Q4	–	Sell	-1,424,213	Closed	-$39.2M	–	273
2017 Q3	$39.2M	Buy	1,424,213 +127,842	+10%	+$3.1M	0.44%	73
2017 Q2	$34.2M	Hold	1,296,371	–	–	0.46%	75
2017 Q1	$27M	Hold	1,296,371	–	–	0.4%	86
2016 Q4	$26.8M	Sell	1,296,371 -23,500	-2%	-$394K	0.43%	71
2016 Q3	$21.4M	Buy	1,319,871 +151,329	+13%	+$2.2M	0.37%	90
2016 Q2	$15.9M	Sell	1,168,542 -15,089	-1%	-$267K	0.3%	102
2016 Q1	$20.7M	Hold	1,183,631	–	–	0.39%	77
2015 Q4	$40.4M	Sell	1,183,631 -899	-0.1%	-$31.2K	0.73%	42
2015 Q3	$35.2M	Buy	1,184,530 +54,121	+5%	+$1.64M	0.71%	41
2015 Q2	$36.1M	Buy	1,130,409 +23,137	+2%	+$595K	0.7%	42
2015 Q1	$23M	Hold	1,107,272	–	–	0.43%	75
2014 Q4	$18.8M	Buy	1,107,272 +417,492	+61%	+$7.29M	0.37%	90
2014 Q3	$13.3M	Buy	689,780 +112,738	+20%	+$2.94M	0.28%	116
2014 Q2	$19.6M	Buy	577,042 +329,589	+133%	+$10.3M	0.42%	85
2014 Q1	$7.79M	Buy	+247,453	New	+$7.73M	0.18%	167

Other funds holding RVNC

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

EWM

Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Polar Capital's RVNC Position: Q3 2020 in Review

Polar Capital reduced its Revance Therapeutics, Inc. (RVNC) stake by 13% in Q3 2020, selling an estimated $4.39M and leaving 1,115,804 shares worth $28.1M. The position accounts for 0.21% of the portfolio, ranked #108.

Polar Capital first reported a position in RVNC in Q1 2014 and has held it in 19 quarters since. The position peaked at $40.4M in Q4 2015. 153 funds tracked by Wall St. Rank hold RVNC as of Q3 2020.

Polar Capital held 1,115,804 shares of Revance Therapeutics, Inc. worth $28.1M as of Q3 2020.
Polar Capital sold 167,409 Revance Therapeutics, Inc. shares in Q3 2020, an estimated $4.39M.
Revance Therapeutics, Inc. made up 0.21% of Polar Capital's portfolio in Q3 2020, its #108 holding.
Polar Capital first reported a position in Revance Therapeutics, Inc. in Q1 2014 and has held it in 19 quarters since.
Polar Capital's Revance Therapeutics, Inc. position peaked at $40.4M in Q4 2015.
153 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2020.

Based on Polar Capital's 13F filing for Q3 2020, filed 16 Nov 2020.